These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 1082656)

  • 41. In vivo effects of hyperthermia on the functional and conformational characteristics of antithrombin.
    Hernández-Espinosa D; Mota R; Miñano A; Ordóñez A; Yélamos J; Vicente V; Corral J
    J Thromb Haemost; 2007 May; 5(5):963-70. PubMed ID: 17472584
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Natural inhibitors of the coagulation system.
    Messmore HL
    Semin Thromb Hemost; 1982 Oct; 8(4):267-75. PubMed ID: 6184781
    [No Abstract]   [Full Text] [Related]  

  • 43. Highly purified antithrombin 3 with heparin cofactor activity prepared by disc electrophoresis.
    Abildgaard U
    Scand J Clin Lab Invest; 1968; 21(1):89-91. PubMed ID: 5637480
    [No Abstract]   [Full Text] [Related]  

  • 44. Measurement of antithrombin III, alpha 2-macroglobulin and alpha 1-antitrypsin in patients with deep venous thrombosis and pulmonary embolism.
    de Boer AC; van Riel LA; den Ottolander GJ
    Thromb Res; 1979; 15(1-2):17-25. PubMed ID: 90398
    [No Abstract]   [Full Text] [Related]  

  • 45. Identification of thrombin residues that modulate its interactions with antithrombin III and alpha 1-antitrypsin.
    Le Bonniec BF; Guinto ER; Stone SR
    Biochemistry; 1995 Sep; 34(38):12241-8. PubMed ID: 7547966
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The inhibitory effect of plasma inhibitor on plasmin activated with streptokinase or urokinase.
    Sumi H; Takada Y; Takada A
    Nihon Seirigaku Zasshi; 1977; 39(5):112-4. PubMed ID: 72149
    [No Abstract]   [Full Text] [Related]  

  • 47. Albumin contamination of a purified human alpha 1-antitrypsin preparation does not affect either structural conformation or the electrophoretic mobility of the inhibitor.
    Finotti P; Pagetta A
    Clin Chim Acta; 1997 Aug; 264(2):133-48. PubMed ID: 9293373
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A new assay for the measurement of total progressive antithrombin.
    Lane JL; Bird P; Rizza CR
    Br J Haematol; 1975 May; 30(1):103-15. PubMed ID: 53064
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of antithrombin III, alpha 1-proteinase inhibitor and heparin on amidolytic activity of nerve growth factor (7S-NGF).
    Long WF; Williamson FB
    Biochem Biophys Res Commun; 1983 May; 113(1):108-13. PubMed ID: 6602610
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Natural coagulation inhibitors: an assessment in patients.
    Losito R; Gattiker H; Bilodeau G; Longpré B
    Ann N Y Acad Sci; 1981; 370():714-9. PubMed ID: 6168229
    [No Abstract]   [Full Text] [Related]  

  • 51. [A study of antithrombin systems during heparin therapy].
    Boneu B; Immaculato F; Sie P; Caranobe C; Chamontin B; Guittard J
    Nouv Presse Med; 1982 Oct; 11(41):3043-6. PubMed ID: 6183640
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The behavior of antithrombin III, alpha 2 macroglobulin, and alpha 1 antitrypsin during cardiopulmonary bypass.
    Pickering NJ; Brody JI; Fink GB; Finnegan JO; Ablaza S
    Am J Clin Pathol; 1983 Oct; 80(4):459-64. PubMed ID: 6194683
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Serum protease inhibitors promote anchorage-independent growth of transformed cells in serum-free medium.
    Chen JK
    Life Sci; 1992; 51(5):375-80. PubMed ID: 1378169
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhibition of urokinase by complex formation with human alpha1-antitrypsin.
    Clemmensen I; Christensen F
    Biochim Biophys Acta; 1976 Apr; 429(2):591-9. PubMed ID: 1083251
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Changes in the protease inhibitor activity of the blood serum in patients with disseminated sclerosis].
    Chapovs'ka TI
    Lik Sprava; 1994; (9-12):118-20. PubMed ID: 7604547
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antithrombin III: a backward glance o'er travel'd roads.
    Seegers WH
    Adv Exp Med Biol; 1975; 52():195-215. PubMed ID: 47704
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of experimental inflammation on the synthesis and distribution of antithrombin III and alpha1-antitrypsin in rabbits.
    Koj A; Regoeczi E
    Br J Exp Pathol; 1978 Oct; 59(5):473-81. PubMed ID: 309765
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antithrombin 3. Protection against death after injection of thromboplastin.
    Mann LT; Jensenius JC; Simonsen M; Abildgaard U
    Science; 1969 Oct; 166(3904):517-8. PubMed ID: 4186074
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sulfated galactan is a catalyst of antithrombin-mediated inactivation of alpha-thrombin.
    Melo FR; Pereira MS; Monteiro RQ; Foguel D; Mourão PA
    Biochim Biophys Acta; 2008 Sep; 1780(9):1047-53. PubMed ID: 18558097
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Simultaneous isolation and partial characterization of antithrombin III and alpha 1-proteinase inhibitor from horse plasma.
    Kurdowska A; Koj A; Jaśkowska M
    Acta Biochim Pol; 1982; 29(1-2):95-103. PubMed ID: 6983800
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.